“Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s714. doi:10.25251/rm8etw25.